Immix Biopharma, Inc. IMMX
8.35 USD -0.22 (-2.57%)
At closeNov 10, 2026, 5:46 PM EST
8.14 -0.21 -2.51%
After hours · Nov 10, 5:46 PM ET
8.13 Day range 8.77
3.23 52-week range 14.47
- YTD
- +59.66%
- 1 year
- +157.72%
News
benzinga.com Immix Biopharma To Present An NXC-201 Abstract At American Society Of Hematology Annual Meeting, December 12-15 ASH Oral Presentation Details:Event 68th ASH Annual Meeting and Exposition, New Orleans, LATitle "45-patient safety and efficacy data for NXC-201 from Nexicart-2, the first U.S. trial of CAR-T in
globenewswire.com Immix Biopharma's NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026 – Data will be presented on Monday, December 14, 2026 at 11:15 AM CDT – LOS ANGELES, CA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a global…
globenewswire.com Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at…
defenseworld.net Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study Immix Biopharma (NASDAQ: IMMX) reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a…
marketbeat.com Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study Immix Biopharma NASDAQ: IMMX reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a…
globenewswire.com Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the…
defenseworld.net Immix Biopharma (NASDAQ:IMMX) Stock Jumps 4.1% – Should You Buy? Shares of Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report) rose 4.1% during trading on Monday. The stock traded as high as $11.37 and last traded at $11.4250. 314,931 shares changed hands…
seekingalpha.com Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript- benzinga.com Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30 Needham analyst Gil Blum maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $21 to $30.
globenewswire.com Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the…
globenewswire.com Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis – 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) –
benzinga.com Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26 Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and raises the price target from $15 to $26.
defenseworld.net Immix Biopharma (NASDAQ:IMMX) Reaches New 12-Month High – Still a Buy? Immix Biopharma, Inc. (NASDAQ: IMMX - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $13.80 and last traded at $13.61, with a…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX). Such investors are advised to…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. (“Immix” or the “Company”) (NASDAQ: IMMX). Such investors are advised…- benzinga.com Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19 Morgan Stanley analyst Judah Frommer maintains Immix Biopharma (NASDAQ:IMMX) with a Overweight and lowers the price target from $20 to $19.
benzinga.com HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25 HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $20 to $25.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX). Such investors are advised to…
businesswire.com IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $IMMX--IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law.
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. (“Immix” or the “Company”) (NASDAQ: IMMX). Such investors are advised…
globenewswire.com Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immix Biopharma, Inc. ("Immix" or the "Company") (NASDAQ: IMMX). Such investors are advised to…
newsfilecorp.com IMMX INVESTIGATION: Securities Fraud Investigation by Block & Leviton Could Allow Immix Biopharma Investors to Recover Losses Boston, Massachusetts--(Newsfile Corp. - July 23, 2026) - Block & Leviton is investigating Immix Biopharma (NASDAQ: IMMX) for potential securities law violations. Investors who have lost money in…
benzinga.com Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21 Needham analyst Gil Blum initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $21.
globenewswire.com Immix Biopharma Investigated by the Portnoy Law Firm LOS ANGELES, July 21, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immix Biopharma , (“ Immix " or the "Company") ( NASDAQ : IMMX ) investors that the firm has initiated an investigation…
globenewswire.com IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc. ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Immix Biopharma, Inc. (“Immix” or the “Company”) (NASDAQ: IMMX) complied with federal securities laws. On July…
benzinga.com Watching Immix Biopharma; Shares Trading Lower, Traders Circulate STAT News Article Titled 'A Most-Wanted Fugitive Appears To Have Been Secretly Working As A Biotech Executive' https://www.statnews.com/2026/07/20/ronald-fischer-rhode-island-fugitive-richard-graydon-biotech/ As of July 17, 2026, Richard Graydon has been terminated and is no longer with the Company for…
benzinga.com Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.
benzinga.com This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzinga's analyst ratings page.
benzinga.com This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts changed outlook on top Wall Street names. See all changes on our analyst ratings page. Check out analysts' views on TRNO, RLMD, TLN, IMMX, CEG.- benzinga.com B of A Securities Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $27 B of A Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $27.
- benzinga.com HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $20 HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $15 to $20.
benzinga.com What's Going On With Immix Biopharma Stock Thursday? Immix Biopharma (IMMX) prices $150M public offering to fund its NXC-201 cell therapy into mid-2028. Read the details.- benzinga.com Immix Biopharma Prices Underwritten Registered Offering Of 16,778,524 Shares At $8.94 Per Share The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissions and other offering expenses, are expected to be $150 million. The offering is expected to close…
- benzinga.com Immix Biopharma Announces That All Four Relapsed/Refractory Al Amyloidosis MRDd-Negative Patients Presented At ASH 2025 Have Converted To Complete Response – Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) –– CR rate now 95% (19 of 20 patients) –– All CRs reached within 1 year of
benzinga.com HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $15 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy and maintains $15 price target.- benzinga.com Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $15 Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and raises the price target from $14 to $15.
- benzinga.com Citizens Reiterates Market Outperform on Immix Biopharma, Maintains $23 Price Target Citizens analyst Reni J. Benjamin reiterates Immix Biopharma (NASDAQ:IMMX) with a Market Outperform and maintains $23 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $15 HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $12 to $15.
- benzinga.com Immix Biopharma Q4 EPS $(0.28) Misses $(0.16) Estimate Immix Biopharma (NASDAQ:IMMX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.16) by 75 percent. This is a 75 percent decrease over losses of $(0.16)…
- benzinga.com Morgan Stanley Initiates Coverage On Immix Biopharma with Overweight Rating, Announces Price Target of $20 Morgan Stanley analyst Judah Frommer initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Overweight rating and announces Price Target of $20.
benzinga.com This Valaris Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Wall Street analysts make changes to top stocks. Check our analyst ratings page for all updates. VAL, BF.B mentioned.
benzinga.com This Truist Financial Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Wall Street analysts upgraded and initiated coverage on top stocks, including Redwire, Zions Bancorporation, Citizens Financial, and Truist Financial.
benzinga.com This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top analysts change outlook on top names. See all analyst rating changes on Benzinga's analyst ratings page. Consider AKTS stock based on analyst views.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session